Author: Fiona Craig

Aeorema Communications (LSE:AEO) has upgraded its expectations for 2026 after delivering a strong first-half performance, with revenue expected to increase 32% year on year to at least £17.4 million. Profit before tax is forecast to reach no less than £1.5 million, reflecting stronger margins, continued demand from international clients and the benefits of restructuring initiatives implemented during 2025. The company also maintained a healthy cash position, providing further support for its growth strategy.

Following the strong start to the year, Aeorema now expects to outperform current market forecasts, guiding for full-year revenue of at least £22 million and profit before tax of no less than £810,000. Management noted that earnings will be significantly weighted towards the first half because of the timing of major events. Activity reached record levels at the Cannes Lions festival, while new projects at SXSW and POSSIBLE Miami, together with increasing contributions from North America, demonstrate the group’s strategy of strengthening long-term client relationships and expanding its presence at leading international events.

The investment outlook remains mixed. While recent cash flow performance has been volatile and profitability trends have weakened compared with historical levels, the company continues to generate accounting profits and maintains a relatively strong balance sheet with modest leverage. Technical indicators point to a mildly positive trend with broadly neutral momentum, although valuation remains demanding because of a high price-to-earnings ratio. This is partly offset by an attractive dividend yield.

About Aeorema Communications

Aeorema Communications is a strategic communications and events group that provides corporate events, brand experiences and film production services to an international client base. Through its Cheerful Twentyfirst and Eventful Limited agencies, the London-based business delivers live, virtual and hybrid events for global brands across a range of industries.

With operations in London, New York and Amsterdam, the company continues to expand its international footprint while focusing on creating long-term partnerships and delivering high-profile events in key global markets.

Jersey Oil & Gas (LSE:JOG) has been granted a six-month extension to the Second Term of its P2170 Verbier licence by the North Sea Transition Authority, extending the licence to 28 February 2027 to match the duration of the P2498 Buchan Horst licence. The extension provides additional time to progress the integrated Area Plan for the Greater Buchan Area and supports the company’s objective of developing a phased production hub centred on the Buchan field.

Jersey Oil & Gas and its joint venture partners are continuing to evaluate the most appropriate development strategy for the Buchan project as they navigate lengthy regulatory approval processes and assess the impact of the UK’s Energy Profits Levy on investment decisions. Engineering studies and work related to further licence extensions are expected to continue into 2027. The company also reiterated its view that changes to the UK’s fiscal and regulatory framework are needed to encourage North Sea investment, safeguard employment and strengthen the country’s long-term energy security.

The investment outlook remains influenced by weak underlying financial metrics, including the absence of revenue and ongoing cash outflows. However, these challenges are partly offset by a strong balance sheet with minimal debt and signs of improving losses and cash burn during 2025. From a technical perspective, the shares remain in an upward trend, although overbought indicators point to the possibility of increased short-term volatility. Valuation remains difficult to assess given the company’s negative earnings and the absence of a dividend yield.

About Jersey Oil & Gas

Jersey Oil & Gas plc is an independent upstream exploration and production company focused on opportunities across the UK Continental Shelf in the North Sea. Its principal asset is the Greater Buchan Area, where the company is pursuing the development of a Buchan-led production hub designed to bring together surrounding resources within a phased development strategy.

By advancing infrastructure-led projects in the North Sea, Jersey Oil & Gas aims to support domestic oil and gas production while contributing to the UK’s long-term energy security and maximising the value of regional resources.

Hikma Pharmaceuticals (LSE:HIK) delivered a solid first-half performance for 2026, with group revenue increasing 4% to $1.728 billion and core operating profit rising 9% to $405 million. Growth was supported by a strong performance in the Branded division, alongside resilient contributions from the Injectables and Hikma Rx businesses. Although reported profit attributable to shareholders edged lower, the company improved cash generation, retained a strong balance sheet, increased its interim dividend and continued its $250 million share buyback programme.

The group accelerated investment in research and development as well as sales and marketing during the period, submitting 48 products for approval and launching 43 new medicines. Hikma also expanded strategic partnerships, particularly across the Middle East and North Africa, to strengthen its product pipeline and broaden its portfolio. Management highlighted the introduction of a new geographically aligned leadership structure, the planned exit from its 503B compounding operations, continued supply chain efficiency initiatives and recent board changes. The company reaffirmed its full-year outlook, expecting modest revenue growth and higher core operating profit, reflecting confidence in its long-term strategy.

The investment outlook remains supported by solid profitability, a healthy balance sheet and positive long-term strategic initiatives, although weaker cash generation and lower cash conversion have tempered the financial picture. Technically, the shares continue to trade in a strong upward trend, but overbought indicators suggest the potential for increased short-term volatility. An attractive valuation, supported by a low price-to-earnings ratio, a dividend yield of around 3.7% and an ongoing share buyback programme, reinforces the company’s longer-term investment appeal.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a UK-headquartered multinational pharmaceutical company specialising in branded and generic medicines. The business has established operations across North America, Europe and the Middle East and North Africa, with particular strength in injectable medicines and complex generic pharmaceuticals.

The company is recognised as a leading supplier of branded medicines across the MENA region, one of the largest providers of generic injectables in the United States and an expanding participant in the European injectables market. Through continued investment in research, manufacturing and commercial capabilities, Hikma aims to broaden patient access to high-quality medicines worldwide.

CAB Payments (LSE:CABP) reported a strong set of interim results for the six months ended 30 June 2026, with total income rising 31% year-on-year to £67.6 million. Adjusted profit after tax increased by 152% to £13.6 million, lifting adjusted return on target capital to more than 26%. The group also benefited from improved operating leverage and wider margins, while maintaining a robust capital position with a CET1 ratio of 21.7%, reinforcing confidence in its medium-term growth objectives.

The company also unveiled a new capital allocation framework and declared its first interim dividend of 2.1p per share, representing around 40% of adjusted first-half earnings. Alongside returning capital to shareholders, CAB Payments continued to expand its international footprint by securing new major clients, extending its correspondent banking relationship with Deutsche Bank, advancing its stablecoin programme and establishing, or planning, new offices in Abu Dhabi, New York, Amsterdam, Guyana and several African markets. These initiatives are intended to support higher transaction volumes despite ongoing macroeconomic uncertainty and delays linked to regional conflicts.

The group’s investment outlook remains balanced. A strong balance sheet with conservative leverage provides financial resilience, although volatile cash generation and inconsistent revenue and margin trends continue to present challenges. Technical indicators are relatively constructive, with the shares trading above key moving averages, while valuation appears reasonable based on earnings multiples, although dividend yield data remains limited.

About CAB Payments Holdings Limited

CAB Payments Holdings plc operates through its subsidiary, Crown Agents Bank, providing specialist cross-border payments and foreign exchange services for businesses and institutions operating across emerging and frontier markets. The bank enables access to complex payment corridors through digital platforms, APIs and tailored financial solutions, supporting transactions in 124 currencies and more than 800 currency pairs.

The group focuses on connecting underserved markets with the global financial system while maintaining a strong emphasis on responsible business practices. CAB Payments holds B Corporation certification, has received a Platinum sustainability rating from EcoVadis and is listed on the London Stock Exchange under the ticker CABP.

Helix Exploration PLC (LSE:HEX) has transitioned its Rudyard helium project in Montana into continuous trailer-filling operations after commencing commercial production in July and completing its first deliveries to an industrial gases customer. The company said every well connected to the pipeline network is now operating at high pressure, with additional development activity expected once regulatory approvals are secured, strengthening Rudyard’s role as a reliable source of recurring revenue.

The company has also started helium tolling operations at its recently acquired Keyes Helium Complex in Oklahoma, where tube trailers are now being filled on a weekly basis, creating an additional revenue stream. Ownership of one of just six operating helium liquefaction plants in the United States gives Helix a strategically integrated position within the supply chain, allowing it to process both internally produced and third-party helium while benefiting from tightening market conditions and the decline of older production sources.

Despite these operational milestones, the company’s overall investment profile remains constrained by weak financial metrics, including the absence of revenue in historical reporting, continued losses and increasing free cash flow outflows. A debt-free balance sheet remains a notable strength, but technical indicators continue to reflect market weakness, with the share price trading below key moving averages and bearish momentum signals. Valuation support is also limited given the company’s negative price-to-earnings ratio and the lack of a dividend.

About Helix Exploration PLC

Helix Exploration PLC is a London-listed helium producer focused on the U.S. market, operating across the helium value chain from production through to liquefaction. Its flagship Rudyard Project in Montana represents the state’s first producing helium field, while the acquisition of the Keyes Helium Complex in Oklahoma has positioned the company among the small group of operators that own and run helium liquefaction facilities in the United States.

By combining upstream production with downstream processing capabilities, Helix aims to capture greater value from its helium resources while offering processing services to third parties. Supported by existing infrastructure and expansion plans, the company is seeking to establish itself as an independent, fully integrated supplier serving the growing North American helium market.

Morgan Advanced Materials (LSE:MGAM) reported a solid set of first-half 2026 results, with organic revenue at constant currency increasing 4.8% to £518.1 million. The group posted an adjusted operating margin of 11.2%, supported by a one-off £8.9 million timing benefit linked to a semiconductor take-or-pay agreement. Adjusted operating profit, earnings per share and leverage reflected continued investment in manufacturing capacity, business simplification initiatives and ERP implementation. Net debt stood at 2.0x EBITDA, while free cash flow remained subdued, although management expects a stronger performance during the second half of the year.

The company said its multi-year simplification programme is now largely complete and remains on course to generate annualised savings of £27 million by the end of 2026. These efficiencies are expected to support Morgan Advanced Materials’ medium-term objectives of delivering growth ahead of GDP, achieving a 12% operating margin by 2028 and maintaining strong returns on capital. Other strategic priorities include completing two significant site transformation projects, expanding centralised procurement, strengthening dedicated growth teams in targeted markets and continuing the strategic review of the Thermal Products division, which could ultimately result in a disposal to improve portfolio quality and long-term profitability.

The investment case remains balanced. Stronger cash generation prospects provide encouragement, although recent pressure on revenue and earnings, combined with leverage, continues to weigh on the financial profile. From a technical perspective, the shares remain in a downward trend despite an attractive valuation supported by a relatively low price-to-earnings ratio and an appealing dividend yield. Management’s outlook points to gradual improvement, but ongoing weakness in semiconductor-related markets, alongside higher financing costs, suggests investors should continue to monitor execution closely.

About Morgan Advanced Materials

Morgan Advanced Materials is a global specialist in engineered materials, bringing together expertise in materials science, manufacturing processes and application engineering to develop critical products for industries including aerospace, energy, rail and industrial manufacturing. Established in 1856, the company operates 57 sites worldwide and employs around 8,100 people, supplying customers with high-performance solutions used in essential infrastructure and advanced technologies.

Its long-standing focus on innovation has enabled the business to play a key role in supporting industrial progress, delivering specialist materials that contribute to the reliability and performance of critical systems across a wide range of global markets.

AstraZeneca (LSE:AZN) shares recovered strongly on Wednesday after a Reuters report said there are “no discussions” with Bristol Myers Squibb (NYSE:BMY) over a possible merger, easing fears that had triggered one of the FTSE 100’s sharpest declines earlier this week.

The rebound came after investors reacted negatively to reports suggesting the two pharmaceutical companies were exploring a deal that could have created one of the world’s largest drugmakers.

Reuters source rejects merger claims

According to Reuters, a senior source familiar with the situation said there are no negotiations taking place between AstraZeneca and Bristol Myers Squibb.

“There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” the source told Reuters on Wednesday, speaking on condition of anonymity.

The comments directly challenged market speculation that emerged after weekend reports suggesting the companies had explored a possible combination. Reuters had previously reported that preliminary discussions had taken place but said it was unclear whether they had continued.

The clarification helped AstraZeneca recover part of Monday’s near-9% decline, its steepest one-day fall since 2020.

Investors questioned the benefits of a deal

Many analysts had struggled to identify a compelling strategic case for combining the two pharmaceutical groups.

AstraZeneca, with a market value of roughly $264 billion, and Bristol Myers Squibb, valued at around $133 billion, would have created a company worth almost $400 billion. However, many in the market argued that AstraZeneca had little to gain from such a transaction.

Jefferies described the reported proposal as “more than a head scratcher,” adding: “if there is one company that doesn’t need financial engineering, it’s AZ.”

Markus Manns, portfolio manager at Union Investment, told Reuters that the proposed merger “does not make strategic or financial sense” and compared it to “the pharmaceutical industry’s equivalent of the FIFA privatisation moment.”

UK shareholders remain focused on AstraZeneca’s standalone growth

For many UK investors, AstraZeneca’s existing growth strategy already offers a clear long-term investment case without the risks associated with a mega-merger.

Lucy Coutts, investment director at JM Finn, told Reuters that “the only advantage for AstraZeneca in this rumoured combination with BMS seems to be to accelerate its U.S. footprint and sales” and added that “BMS shareholders would be the winners of any combination with AZN.”

That sentiment was reflected in Monday’s trading, when AstraZeneca was among the FTSE 100’s biggest fallers while Bristol Myers Squibb shares moved sharply higher in the United States.

Regulatory obstacles would have been significant

Even if discussions had progressed, analysts believe a transaction of this size would have faced substantial regulatory scrutiny.

Both companies compete directly in key oncology markets through AstraZeneca’s Imfinzi and Bristol Myers Squibb’s Opdivo, while also marketing the only two approved anti-CTLA-4 cancer therapies.

Competition experts have suggested that significant asset disposals would probably have been required before regulators would approve any merger.

Strong fundamentals remain the key investment story

The merger speculation has also overshadowed AstraZeneca’s recent operational performance.

The company recently reported second-quarter earnings per share of $2.63, comfortably ahead of the $2.48 consensus estimate, while maintaining its ambition of generating $80 billion in annual revenue by 2030.

Alongside its recent New York Stock Exchange listing and plans to invest $50 billion in U.S. research, manufacturing and development by 2030, AstraZeneca continues to pursue expansion through organic growth rather than transformational acquisitions.

For UK investors, Wednesday’s recovery suggests the market is once again refocusing on the company’s long-term fundamentals rather than an acquisition that, according to Reuters’ latest report, was never under active discussion.